Jinfu Diao1, Tianbao Xia2, Hongwei Zhao3, Jialin Liu4, Bin Li3, Zhiwen Zhang4. 1. Chinese PLA Medical School, Department of Neurosurgery, The First Affliated Hospital of Chinese PLA General Hospital 51 Fuchengmen Road, Haidian District, Beijing 100048, China ; Department of Neurosurgery, General Hospital of Armed Police Forces 69 Yongding Road, Haidian District, Beijing 100039, China. 2. Department of Dermatology, 306 Hospital of PLA Chaoyang District, Beijing 100101, China. 3. Department of Neurosurgery, 306 Hospital of PLA Chaoyang District, Beijing 100101, China. 4. Chinese PLA Medical School, Department of Neurosurgery, The First Affliated Hospital of Chinese PLA General Hospital 51 Fuchengmen Road, Haidian District, Beijing 100048, China.
Abstract
AIMS: Since the poor prognosis of glioma, our study was aimed to find out the role of HLA-DR in the prognosis of glioma patients that may contribute to the timely post-operative treatment on the glioma patients. METHODS: 60 glioma patients were enrolled in the prospective cohort study. Western blotting was used to detect the content of HLA-DR. Kaplan-Meier curve was adopted to evaluate the effects of HLA-DR on the survival time of glioma patients. Cox regression analysis was used to evaluate the roles of clinical features and HLA-DR in the pathogenesis of glioma. RESULTS: The expression level of HLA-DR was higher in tumor tissue, compared with normal tissues (P<0.05). Moreover, expression levels of HLA-DR were correlated with the factors of pathological degree, Enneking staging and KPS score. The survival rate of patients with high content of HLA-DR was lower than those of patients with low content of HLA-DR. Cox regression analysis indicated that Enneking staging and HLA-DR were all associated with the prognosis of glioma (HR=14.43, 95% CI=1.05-199.16; HR=21.39, 95% CI=2.07-220.76). CONCLUSION: HLA-DR may serve as a biomarker for the prognosis of glioma patients.
AIMS: Since the poor prognosis of glioma, our study was aimed to find out the role of HLA-DR in the prognosis of gliomapatients that may contribute to the timely post-operative treatment on the gliomapatients. METHODS: 60 gliomapatients were enrolled in the prospective cohort study. Western blotting was used to detect the content of HLA-DR. Kaplan-Meier curve was adopted to evaluate the effects of HLA-DR on the survival time of gliomapatients. Cox regression analysis was used to evaluate the roles of clinical features and HLA-DR in the pathogenesis of glioma. RESULTS: The expression level of HLA-DR was higher in tumor tissue, compared with normal tissues (P<0.05). Moreover, expression levels of HLA-DR were correlated with the factors of pathological degree, Enneking staging and KPS score. The survival rate of patients with high content of HLA-DR was lower than those of patients with low content of HLA-DR. Cox regression analysis indicated that Enneking staging and HLA-DR were all associated with the prognosis of glioma (HR=14.43, 95% CI=1.05-199.16; HR=21.39, 95% CI=2.07-220.76). CONCLUSION: HLA-DR may serve as a biomarker for the prognosis of gliomapatients.
Authors: Jin-Ping Lai; Abdul M Oseini; Catherine D Moser; Chunrong Yu; Sherine F Elsawa; Chunling Hu; Ikuo Nakamura; Tao Han; Ileana Aderca; Hajime Isomoto; Megan M Garrity-Park; Abdirashid M Shire; Jia Li; Schuyler O Sanderson; Alex A Adjei; Martin E Fernandez-Zapico; Lewis R Roberts Journal: Hepatology Date: 2010-11 Impact factor: 17.425
Authors: P Birner; B Gatterbauer; G Oberhuber; M Schindl; K Rössler; A Prodinger; H Budka; J A Hainfellner Journal: Cancer Date: 2001-07-01 Impact factor: 6.860
Authors: Zaki N Hasan; Haider H Zalzala; Hyam R Mohammedsalih; Batool M Mahdi; Laheeb A Abid; Zena N Shakir; Maithem J Fadhel Journal: Neurosciences (Riyadh) Date: 2014-10 Impact factor: 0.906
Authors: Margaret R Dunne; Adriana J Michielsen; Katie E O'Sullivan; Mary Clare Cathcart; Ronan Feighery; Brendan Doyle; Jenny A Watson; Naoimh J O'Farrell; Narayanasamy Ravi; Elaine Kay; John V Reynolds; Elizabeth J Ryan; Jacintha O'Sullivan Journal: Cancer Immunol Immunother Date: 2017-03-18 Impact factor: 6.968
Authors: Diana P Saraiva; António Jacinto; Paula Borralho; Sofia Braga; M Guadalupe Cabral Journal: Front Immunol Date: 2018-11-13 Impact factor: 7.561
Authors: Zuzana Mikulkova; Gayane Manukyan; Peter Turcsanyi; Milos Kudelka; Renata Urbanova; Jakub Savara; Eliska Ochodkova; Yvona Brychtova; Jan Molinsky; Martin Simkovic; David Starostka; Jan Novak; Ondrej Janca; Martin Dihel; Pavlina Ryznerova; Lekaa Mohammad; Tomas Papajik; Eva Kriegova Journal: Sci Rep Date: 2021-01-11 Impact factor: 4.379